- recruitingHuman Pharmacology (Phase I)- Other
M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)
This early-stage clinical trial is testing a new drug called M9466 for adults with advanced solid tumours. Researchers want to find out how safe the medicine is, what dose works best, and how it behaves when given either on its own or with other cancer treatments.
Spain - authorisedHuman Pharmacology (Phase I)- First administration to humans
Study of safety and tolerability of BCA101 monotherapy and in combination therapy in patients with EGFR-driven advanced solid tumors
This early-stage clinical trial tests a new drug called BCA101 for advanced solid cancers. It is the first time the medicine is being tested in humans. Doctors want to see if BCA101 is safe, what side effects it causes, and how well it is tolerated on its own or with other treatments.
Spain · France - authorisedHuman Pharmacology (Phase I)- First administration to humans
A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDYTO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS
This early-stage clinical trial tests a new drug called SIM0505 in adults with advanced solid tumours. It is the first time the medicine is given to people. Researchers want to find a safe dose, check for side effects, and see if it can help slow down or shrink cancer.
Italy · Poland · France - authorisedHuman Pharmacology (Phase I)- First administration to humans
First-in-Human Trial of DS1025a in Participants with Advanced Solid Tumors
This clinical trial tests a new drug called DS1025a in humans for the first time. It is for adults with advanced solid tumours that cannot be removed by surgery or have spread. Researchers want to find out if the drug is safe, learn its side effects, and find the right dose.
France - authorisedPhase I and Phase II (Integrated)- First administration to humans
First-in-human study of ATX-898 as monotherapy and in combination with other anti-neoplastic agents, in participants with advanced solid tumors
This early-stage clinical trial tests a new cancer drug called ATX-898 for the first time in humans. It looks at whether the drug is safe when taken alone or alongside existing cancer medicines. It is open to adults with advanced solid tumours who need new treatment options.
Netherlands · Spain · France - authorisedHuman Pharmacology (Phase I)- First administration to humans
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
This early-stage clinical trial is testing a new experimental medicine called PF-08046033 for the first time in humans. It is for adults with advanced solid tumours. Doctors want to find out if the drug is safe, what dose is best, and how the body handles it.
Netherlands · France · Spain - recruitingHuman Pharmacology (Phase I)- Other
A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults
This study is looking at a new drug, BAY 2416964, together with a common cancer treatment, pembrolizumab. It aims to see if this combination is safe, how it works in the body, and if it can help adults with advanced solid cancers. It's an early-stage study.
Italy - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors
This early-stage study is looking at a new medicine called IK-930 for people with advanced cancers. It's the very first time this medicine is being given to people, to check if it's safe and how it works in the body.
Netherlands · France · Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab and/or Standard Therapies Including Chemotherapy and/or Immunotherapy in Participants with Locally Advanced or Metastatic Solid Tumors
This study is testing a new drug, ASP1570, on its own and with other cancer treatments for advanced solid tumours. It aims to see how safe the new drug is and how well it works to shrink tumours or stop them from growing. It's for adults aged 18 and over.
Spain · France - recruitingHuman Pharmacology (Phase I)- First administration to humans
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors
This early-stage study is testing a new unproven medicine called RP-1664 for people with advanced solid tumours that have spread. We want to check its safety, how it moves through the body, and if it shows any early signs of helping to shrink tumours. It's the first time this drug is being given to humans.
Denmark - recruitingHuman Pharmacology (Phase I)- Other
Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors
This study is testing a new combination of two medicines, PM14 and atezolizumab, for people with advanced cancers that have already been treated. Doctors want to see if it's safe, how well people tolerate it, and if it helps treat these cancers.
Spain - recruitingHuman Pharmacology (Phase I)- Other
A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)
This study is for people with advanced cancers that have spread. Researchers are testing a new combination of medicines (Brigimadlin with Ezabenlimab, and sometimes another drug) to see if they are safe and what dose works best.
Netherlands · Germany · France - recruitingHuman Pharmacology (Phase I)- First administration to humans
Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors
This study is testing a new medicine called GEN1056 for people with advanced cancers that have spread. It's the first time this medicine is being given to humans, to see if it's safe and if it can help fight cancer. All adults aged 18 and over can take part.
Spain - recruitingPhase I and Phase II (Integrated)- Other
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors
This study is testing new combinations of medicines for advanced solid cancers. It looks at how safe the treatments are and how well they shrink or control the cancer. The aim is to find better ways to treat these cancers.
Italy · France · Belgium - recruitingHuman Pharmacology (Phase I)- First administration to humans
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumors
This study is testing a new medicine called RP3, sometimes with another medicine called Nivolumab, for people with advanced cancers. It's the very first time these treatments are being given to humans, to see how safe they are and what effects they have.
Spain · France · Greece - recruitingHuman Pharmacology (Phase I)- First administration to humans
First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors
This study is looking into a new medication called DS-1471a for people with advanced cancers. It's the very first time this drug will be given to humans, to see if it's safe and how it works in the body.
Belgium · Spain · France - active not recruitingPHASE1
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
This study is looking into new ways to treat advanced cancers that have a specific genetic change called KRAS p.G12C. It's testing a drug called sotorasib, either by itself or with other treatments, to see how safe and effective they are for adults.
United States · Australia · Austria - recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label, Phase 2 Basket Study of MK‑7684A, a Co formation of Vibostolimab (MK‑7684) With Pembrolizumab (MK‑3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (KEYVIBE 005)
This study, called KEYVIBE 005, is testing a new combination of medicines (MK-7684A, which includes vibostolimab and pembrolizumab) for people with advanced solid tumours. Researchers want to see how well this new treatment shrinks tumours and stops them from growing, either alone or with other cancer therapies.
Spain · Italy · Germany - recruitingHuman Pharmacology (Phase I)- Other
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
This study looks at a new medicine called Tuvusertib for people with advanced solid tumours. It aims to understand how the body uses and gets rid of the medicine, and how much of it reaches the bloodstream when taken by mouth compared to other ways. This is an early-stage study.
Hungary - recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumors
This study is testing a new medicine called HST-1011, by itself and with another medicine called Libtayo, for people with advanced cancers. Researchers want to see if these treatments are safe, how they work in the body, and if they help shrink tumors.
Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors
This study is testing a new medicine, ADCT-901, for people with advanced cancers that have spread. It's the first time this medicine is being given to humans, to see how safe it is, what side effects it has, and if it helps shrink tumours.
Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors
This study is looking for new ways to treat advanced cancers. It's testing a new medicine called PM14 given through a drip. Researchers want to find the right dose and see how it works in the body and if it helps people with advanced solid tumours.
Spain · France - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
This study is testing a new medicine, HFB200301, for adults with advanced cancers. It will check if the medicine is safe and how it works, both on its own and with another cancer drug called Tislelizumab.
Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors
This study is looking into a new medication called TNO155 for adults who have advanced solid cancers that have spread. It’s a very early-stage study to find the best dose and check its safety. We want to see how the body handles this new medicine.
Netherlands · Italy · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
Phase 1/1b Multiple-Ascending Dose Study of DF6215 in Patients With Advanced Solid Tumors
This early-stage study is looking at a new medicine called DF6215 for people with advanced cancers that have spread. Researchers want to find a safe dose and see how it works in the body.
France - recruitingHuman Pharmacology (Phase I)- First administration to humans
A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, how it acts on different tumors in participants with advanced solid tumors
This study is the first time a new medicine, BAY2965501, is being tested in people. It aims to find out if it's safe, what dose works best, and how it affects the body in people with advanced solid cancers.
Belgium · Spain - recruitingPhase I
A first-in-human, phase 1/2, multicenter, open-label, dose escalation, confirmation and expansion study to evaluate the safety, pharmacokinetics and antitumor activity of TH9619 in subjects with advanced solid tumors (ODIN)
This study is testing a new drug, TH9619, for people with advanced cancer. It's the first time it’s being given to humans, aiming to see if it’s safe, how it works in the body, and if it can help fight cancer.
United Kingdom · France · Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors
This study is testing a new medicine, LB101, for people with advanced cancers that have spread. Researchers want to see if it's safe, how much can be given, and if it helps to slow or stop cancer growth. It's an early-stage study.
France - recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
This study is testing a new drug, BI 1910, for people with advanced cancers. It will check how safe the drug is, what side effects it causes, and how much of it the body can handle, both on its own and when given with another cancer drug.
Denmark · Poland · Spain - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.
This study is looking at a new medicine called BMS-986158 for people with advanced cancers. Researchers want to see if eating food at the same time changes how well the body takes in the medicine. It's an early-stage study to understand the medicine better.
Spain - recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
This study is testing a new medicine, BMS-986253, alongside existing cancer treatments (Nivolumab and Ipilimumab) for advanced cancers. Doctors want to see how safe the combined medicines are and if they help shrink tumors. It's an early-stage study to gather important information.
Italy · Germany · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
This study is looking at a new medicine, MK-0482, for people with advanced cancer. It will be tested alone and with another common cancer drug, pembrolizumab. The goal is to see if these treatments are safe and how they work in the human body. This is a very early stage of research.
Spain · Italy - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Different Doses of these Medications can be Tolerated by the Body
This study is testing a new medicine, ZL-1218, sometimes given with another drug called pembrolizumab, for people with advanced cancers. Doctors want to find a safe dose and see how well people tolerate it, as this is the first time these drugs are being used in humans.
Spain - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Selected Advanced Solid Tumors
This early-stage study is testing a new medicine called mipasetamab uzoptirine for people with advanced solid tumours. Researchers want to see if it's safe, how much can be given, and if it helps fight cancer, either alone or with other treatments.
France · Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, First-In-Human, Multi-Part, Open Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
This study is testing a new drug (DF6002) for advanced cancers, alone or with an existing drug (Nivolumab). It's looking to see if it's safe, how it moves through the body, and if it helps shrink tumors. It's an early-stage trial for people with solid tumors.
France · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer
This study is looking for the right dose of a new medicine, BI 1821736, for people with advanced cancers that have spread. It also wants to see if this medicine can help treat these cancers.
Sweden · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors
This study is testing a new medicine called HFB200603, both on its own and with another medicine called Tislelizumab. It's for adults with advanced solid cancers. This is a very early study, to see how safe the medicine is and what effects it has on the body.
Italy · Spain - recruitingPHASE1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new medicine, INCA33890, for people with advanced or spreading solid cancers. Doctors want to see how safe the medicine is, what side effects it causes, and find the best dose to give.
United States · China · Denmark - authorisedPhase I and Phase II (Integrated)- Other
C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors
This study is testing a new combination of treatments, including a medicine called PF-08634404, for people with advanced solid tumours. It aims to see how safe the treatments are and how well they work together against cancer.
Italy · Spain · France - not yet recruitingPHASE1, PHASE2
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
This study is testing a new drug, LCB02A, for people with advanced cancers that haven't responded to usual treatments. It aims to find the right dose and see if it helps shrink tumors by targeting a specific protein called Claudin 18.2.
United States · Canada · South Korea - active not recruitingPHASE1
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
This study looks at a new drug, ABBV-400, for advanced cancers like lung and bowel cancer. We're checking how safe it is and if it helps shrink tumours, both on its own and with another drug.
United States · Australia · France - active not recruitingPHASE1, PHASE2
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
This study is looking at a new drug, BMS-986449, by itself and with another drug, nivolumab, for people with advanced cancers. Researchers want to see if these treatments are safe and effective. It's for patients whose cancer hasn't responded to usual treatments.
United States · Belgium · France - recruitingPHASE2
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
This study looks at continuing treatment with sotorasib, sometimes with a drug called panitumumab, for people with advanced cancers that have a specific genetic change (KRAS p.G12C). It checks how safe the treatments are and if they're well-tolerated.
United States · Australia · France - recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This study is testing a new drug, VVD-133214, for advanced solid tumours, including a type of bowel cancer. It looks at safety, how the body handles the drug, and if it can help shrink tumours. It's an early-stage study, sometimes testing the new drug with other standard treatments.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
This study is testing a new drug, DT-7012, both on its own and with another cancer drug, for people with advanced solid tumours. It aims to see if it's safe, what dose works best, and how well it treats the cancer. This is an early-stage study.
United States · Australia · France - recruitingPHASE1
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new cancer medicine, TEV-56278, on its own and with another medicine called pembrolizumab, for people with advanced solid tumours. Researchers want to see if it's safe, what dose works best, and if it can shrink tumours.
United States · Canada - active not recruitingPHASE1
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
This study is testing a new drug, BAY2965501, for advanced cancers like skin, kidney, stomach, and lung cancer. It aims to find a safe dose, how it affects the body, and if it helps shrink tumors. The drug works by boosting the body's own immune cells to fight cancer.
United States · Belgium · China - active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
United States · Australia · Belgium - recruitingPHASE1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
This study is testing a new drug called Calderasib, alone or with other treatments, for advanced cancers with a specific gene change (KRAS G12C). It's looking at how safe and effective these treatments are.
United States · Argentina · Australia - recruitingPHASE1
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
This study looks at a new treatment called MK-0472 for advanced or spreading cancers. It's given alone or with other medicines like pembrolizumab or MK-1084 to see how well it works and if it's safe.
United States · Canada · Chile